Q-omics provides the consensus-scored MIR6810 profile across patient tissues and cancer cell-line models. MIR6810 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, MIR6810 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, MIR6810 RNA expression shows 8,009 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight OV, COAD, and ESCA as cancer lineages where MIR6810 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6810 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6810 survival associations across molecular data types. MIR6810 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6810 RNA expression–survival associations across cancer types. High MIR6810 expression shows unfavorable associations in OV, THYM, BRCA and BLCA, but favorable associations in HNSC and GBM. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for MIR6810 RNA expression.
This table summarizes MIR6810 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6810. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6810 shows higher tumor expression in COAD, BRCA, CHOL, STAD, PRAD and KIRP. The COAD box plot shows higher MIR6810 RNA expression in tumor versus normal tissue (log2 FC = +0.288, t-test p = .005).
This table shows molecular features associated with MIR6810 in patient tissues and cancer cell lines. In patient samples, MIR6810 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
